{
  "nctId": "NCT03309007",
  "briefTitle": "A Double-Blind, Placebo-Controlled Trial of Anti-Aging, Pro-Autophagy Effects of Metformin in Adults With Prediabetes",
  "officialTitle": "A Double-Blind, Placebo-Controlled Trial of Anti-Aging, Pro-Autophagy Effects of Metformin in Adults With Prediabetes",
  "protocolDocument": {
    "nctId": "NCT03309007",
    "filename": "Prot_SAP_002.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2018-05-08",
    "uploadDate": "2023-10-06T14:30",
    "size": 303120,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03309007/document/Prot_SAP_002.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 25,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2017-09-01",
    "completionDate": "2020-08-20",
    "primaryCompletionDate": "2020-08-20",
    "firstSubmitDate": "2017-07-07",
    "firstPostDate": "2017-10-13"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Adults with prediabetes (defined as an A1c of 5.7-6.4%)\n* BMI between 27 and 40 kg/m2 (inclusive).\n\nExclusion Criteria:\n\n* Prior treatment with metformin or other diabetes medications,\n* Pregnancy,\n* Significant renal dysfunction (Serum Creatinine \\> 1.3 mg/dl for women, \\> 1.4 mg/dl for men),\n* Severe hepatic dysfunction (aspartate amnotransferease \\[AST\\] or alanine aminotransferase \\[ALT\\] \\> 3 times the upper limit of normal),\n* Ongoing alcohol or substance abuse,\n* Inflammatory bowel disease,\n* Ongoing glucocorticoid therapy,\n* Or inability to render informed consent.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "30 Years",
    "maximumAge": "70 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Change in Leucocyte LC3 Score",
        "description": "During the process of autophagy, autophagosomes engulf cytoplasmic components and concomitantly, the cytosolic form of LC3 (LC3-I) is conjugated to phosphatidyl ethanolamine, resulting in the autophagosomal membrane-bound form (LC3-II). LC3-II is a widely used marker to monitor autophagosome formation by quantitation of the number of LC3-labeled puncta (autophagosomes, or \"dots\") per cell detected by fluorescence microscopy. An increase in LC3 puncta formation denotes an increase in autophagic activity.",
        "timeFrame": "Data will be collected at 0 and 12 weeks and analyzed within 8 weeks of sample collection."
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 1
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 39,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:29:08.209Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}